ArticleFrontiers in immunology2026

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.

Arielle Urman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.